A naked DNA vaccine delivered by gene gun into antigenpresenting cells (APCs) has emerged as an attractive strategy for antigen-specific cancer immunotherapy. However, APCs have a limited lifespan, hindering their long-term ability to prime antigen-specific T cells. Furthermore, the potency of DNA vaccines is limited by their inability to process and present antigens. Interleukin-6 (IL-6) could play a role in immunity and cell apoptosis. We explored how the DNA vaccine encodes IL-6 to a model tumor antigen, human papilloma virus type-16 (HPV-16) E7. Mice vaccinated with IL-6/E7 DNA exhibited dramatic increases in E7-specific T-cell immunities, anti-E7 antibody responses, and impressive anti-tumor effects against E7-expressing tumors. The in vitro results revealed that IL-6 enhances DNA vaccine potency through the major histocompatibility complex class I pathway via direct and cross-priming effects. In addition, the delivery of IL-6/E7 DNA prolonged the survival of transduced dendritic cells (DCs) in vivo. Our results indicated that the IL-6/E7 DNA vaccine combined the mechanisms of enhancing antigen processing and presentation with prolonging the survival of DCs. Using IL-6 represents an innovative approach to enhancing DNA vaccine potency and holds promise for cancer prevention and immunotherapy.
INTRODUCTION
The ideal cancer treatment should be able to eradicate systemic tumors at multiple sites in the body and have the specificity to discriminate between neoplastic and non-neoplastic cells. In this regard, antigen-specific cancer immunotherapy represents an attractive approach for treatment. Activating antigen-specific T-cell-mediated immune responses allows the killing of tumors associated with a specific antigen. 1 Intradermal administration of DNA vaccines using a gene gun can efficiently deliver specific genes into professional antigen-presenting cells (APCs) in vivo. 2 Among the concerns about DNA vaccines is their limited potency. Several strategies have been applied to increase the potency of DNA vaccines, such as targeting an antigen by fusing molecules to enhance antigen processing, 3, 4 targeting antigens for rapid intracellular degradation, 5 directing antigens to APCs by fusion to ligands for APC receptors 6 or to a pathogen sequence such as fragment C of tetanus toxin, 7 co-injecting cytokines, 8 and administration with CpG oligonucleotides. 9 In our previous studies, we used the gene gun approach to test several strategies that are able to route human papilloma virus type-16 (HPV-16) E7 model antigen and result in enhanced E7-specific CD8 + T-cell-mediated immune responses and anti-tumor effects. 3, 10, 11 Another potential strategy to enhance DNA vaccine potency is to prolong dendritic cell (DC) survival by administering the DNA encoding the antigen with DNA encoding inhibitors of apoptosis to DCs. 12 Recently, combined strategies for enhancing the effects of DNA vaccine have been introduced in the development of cancer vaccines and immunotherapy.
Interleukin-6 (IL-6), a secreting cytokine, plays an important role in the expansion and activation of T cells and differentiation of B cells. 13, 14 IL-6 can inhibit T-cell apoptosis via the IL-6/soluble IL-6 receptor. 15 IL-6 has also been shown to protect cells from apoptosis via the myeloid cell leukemia-1 (Mcl-1) pathway. 16 It seems that IL-6 might be able to enhance anti-tumor immunity through its various functions in a variety of cells.
In this study, we tested IL-6 for its ability to enhance antigen processing and presentation and to prolong DC survival for E7-specific T-cell immune responses when it was linked with E7 in the DNA vaccine strategy. We chose HPV-16 E7 as a model antigen because HPVs, particularly HPV-16, are associated with a majority of cervical cancers, and E7 is essential for the induction and maintenance of cellular transformation. Effective vaccines against E7 can potentially control HPV infections and HPV-associated lesions.
are shown in Figure 1a . As shown in Figure 1b , mice vaccinated with IL-6/E7 DNA generated higher numbers of E7-specific IFN-γ-secreting CD4 + T-cell precursors than mice in the other DNAvaccinated groups [8.0 ± 2.1 for naïve group, 12.5 ± 2.1 for no insert group, 11.0 ± 2.1 for E7 group, 5.5 ± 1.4 for IL-6 group, 6.5 ± 1.4 for E7 mixed with IL-6 group, 8.5 ± 1.4 for Mcl-1/E7 group, 77.0 ± 12.0 for IL-6/E7 group, P < 0.05 one-way analysis of variance (ANOVA)]. Mice immunized with IL-6/E7 DNA also generated higher numbers of E7-specific IL-4-secreting CD4 + T-cell precursors than the other groups (16.0 ± 2.8 for naïve group, 22.5 ± 2.1 for no insert group, 22.0 ± 3.5 for E7 group, 21.5 ± 2.1 for IL-6 group, 26.5 ± 2.8 for E7 mixed with IL-6 group, 18.5 ± 2.8 for Mcl-1/E7 group, 292.0 ± 16.5 for IL-6/E7 group, P < 0.01 one-way ANOVA) (Figure 1c) .
Representative figures from flow cytometry analysis for E7-specific IFN-γ-secreting CD8 + T-cell precursors are shown in Figure 1d . Mice vaccinated with IL-6/E7 DNA generated higher numbers of E7-specific IFN-γ-secreting CD8 + T-cell precursors than mice vaccinated with the other DNA vaccines (4.0 ± 2.1 for naïve group, 6.0 ± 2.1 for no insert group, 6.5 ± 1.4 for E7 group, 4.0 ± 1.4 for IL-6 group, 9.0 ± 2.8 for E7 mixed with IL-6 group, 124.0 ± 6.3 for Mcl-1/E7 group, 432.5 ± 15.4 for IL-6/E7 group, P < 0.01 one-way ANOVA) (Figure 1e ).
IL-6/E7 DNA enhances the E7-specific antibody responses
As shown in Figure 1f , the titers of anti-E7 antibody generated by the IL-6/E7 DNA vaccine were significantly higher than those generated by other DNA vaccines (for 1:100 dilution, naïve 0.434 ± 0.027, no insert 0.418 ± 0.021, E7 0.454 ± 0.037, IL-6 0.403 ± 0.025, E7 mixed with IL-6 0.415 ± 0.016, 0, Mcl-1/E7 0.425 ± 0.028, IL-6/E7 1.063 ± 0.050, P < 0.01 one-way ANOVA).
Enhanced E7 antigen through the MHC I pathway in cells transfected with IL-6/E7 DNA or in dendritic cells pulsed with IL-6/E7 protein At an effector-to-target ratio of 45:1, 293 D b K b cells transfected with IL-6/E7 DNA generated significantly higher percentages of specific lyses (57.2 ± 6.5% versus 9.4 ± 1.3%, P < 0.01 oneway ANOVA) than cells transfected with wild-type E7 DNA © The American Society of Gene Therapy cells transfected with IL-6/E7 DNA also generated a significantly higher percentage of specific lyses than DCs pulsed with 50 µg/ml of lysates of 293 D b K b cells transfected with wild-type E7 DNA construct (45.5 ± 2.0% versus 8.8 ± 0.3%, P < 0.01 oneway ANOVA) (Figure 2b ).
IL-6/E7 DNA enhances tumor protection against TC-1 tumor cells
To determine whether the observed enhancement of E7-specific T-cell immunity could translate into a significant E7-specific protective anti-tumor effect, we performed an in vivo tumor protection experiment. As shown in Figure 3a , 100% of mice receiving IL-6/E7 DNA vaccination, when challenged with TC-1 tumor cells, remained tumor-free for 60 days afterward. Only 40% of the mice receiving Mcl-1/E7 remained tumor-free 60 days after the TC-1 challenge. All mice in the other groups, including the wild-type E7 group, developed tumors within 14 days of TC-1 tumor challenge.
CD8 + T cells, CD4 + T cells, and natural killer cells are essential for the anti-tumor effects by IL-6/E7 DNA
To determine the subset of lymphocytes important for the antitumor effects, we performed in vivo antibody (Ab) depletion experiments. 3 As shown in Figure 3b , all naïve mice and all mice depleted of CD8 + T cells grew tumors within 14 days after the tumor challenge. In addition, 20% of mice depleted of CD4 + T cells and 40% of mice depleted of natural killer 1.1 + cells developed tumors within 60 days of tumor challenge.
IL-6/E7 DNA vaccine leads to significant reduction of pulmonary tumor nodules
We further assessed the therapeutic potential of IL-6/E7 DNA vaccine by using a previously described lung hematogenous spread model. 17 The representative pulmonary tumor nodules in each group are shown in Figure 4a . As shown in Figure 4b , mice treated with IL-6/E7 (153.6 ± 18.2 mg) showed significantly lower lung weights than mice treated with the other DNA vaccines (wild-type E7 630.5 ± 19.5 mg, Mcl-1/E7 395.0 ± 20.5 mg, P < 0.001, one-way ANOVA). Mice treated with IL-6/E7 (1.5 ± 1.2) also exhibited significantly fewer pulmonary tumor nodules than mice treated with the other DNA vaccines (wild-type E7 87.6 ± 7.4, Mcl-1/E7 54.0 ± 5.0, P < 0.001, one-way ANOVA) (Figure 4c ). In addition, the mice vaccinated with Mcl-1/E7 revealed lower numbers of pulmonary tumor nodules than the group vaccinated with wild-type E7 (P < 0.05, one-way ANOVA). Figure 5b , there is no significant difference in the numbers of CD11c and GFP + cells in the inguinal lymph nodes at day 1 after vaccination. However, 5 days after gene gun vaccination, we found greater percentages of GFP + CD11c + cells in lymph nodes harvested from mice vaccinated with the Mcl-1/E7/GFP DNA and IL-6/E7/GFP than in lymph nodes harvested from mice vaccinated with E7/GFP and GFP-only DNA (P < 0.01, one-way ANOVA).
We further assayed for the apoptotic cells in CD11c + GFP + cells derived from the draining lymph nodes of various vaccinated mice. Mice vaccinated with DNA encoding IL-6/E7/GFP or Mcl-1/E7/GFP demonstrated significantly lower percentages of apoptotic cells than mice vaccinated with GFP or E7/GFP DNA (P < 0.01, one-way ANOVA) (Figure 5c ).
CD11c-enriched cells from IL-6/E7/GFP and
Mcl-1/E7/GFP DNA-vaccinated mice could activate an E7-specific CD8 + T-cell line Using various DNA-vaccinated mice, we evaluated the ability of CD11c-enriched cells to stimulate INF-γ secretion from an E7-specific CD8 + T-cell line. As shown in Figure 5d , we compared CD11c-enriched cells 5 days after gun vaccination. Those isolated from mice vaccinated with IL-6/E7/GFP and Mcl-1/ E7/GFP DNA were more effective in activating the E7-specific CD8 + T-cell line to secrete IFN-γ than those isolated from mice vaccinated with GFP and E7/GFP DNA (P < 0.001, one-way ANOVA).
IL-6/E7 combined with ETA(dII)/E7 DNA generated better anti-tumor effects than IL-6/E7 DNA only and ETA(dII)/E7 DNA only
We finally compared the chimeric E7 DNA vaccines in tumor treatment experiments. As shown in Figure 6a , mice vaccinated with IL-6/E7 mixed with exotoxin A (ETA)(dII)/E7 DNA (129.6 ± 4.9 mg) had the lowest lung weights. Those vaccinated with IL-6/E7 DNA had lung weights of 167.9 ± 4.1 mg, and those vaccinated with ETA(dII)/E7 DNA had lung weights of 177.9 ± 6.4 mg (P < 0.001). In addition, mice vaccinated with IL-6/E7 mixed with ETA(dII)/E7 DNA (6.2 ± 0.8) had the fewest pulmonary tumor nodules (Figure 6b ). Figure 7 , the percentages of specific lyses of IL-6/E7 protein-pulsed cytotoxic cells on CaSki cells were significantly higher than those of E7 protein-pulsed E7-specific cytotoxic cells.
IL-6/E7 generates higher killing effects on cervical cancer cells than E7 in cytotoxic T-lymphocyte assays We finally performed cytotoxic T-lymphocyte (CTL) assays using various protein-pulsed cytotoxic T cells as effector cells and CaSki cells as target cells. As shown in

DISCUSSION
Our results support our hypothesis that an IL-6/E7 DNA vaccination strategy is an effective means of combating tumors. It combines strategies for enhancing antigen processing and presentation and prolonging DC life. The treatment is capable of enhancing antigen-specific immune responses and anti-tumor effects to a greater degree than a wild-type E7 DNA vaccination only. IL-6 linked with E7 generates strong E7-specific CD4 + and CD8 + T-cell immunities. Enhanced processing of the E7 antigen may be attributed to IL-6, resulting in increased major histocompatibility complex:peptide presentation to T lymphocytes (Figure 2 ). DC life is also prolonged via inhibition of apoptosis by IL-6, resulting in an increased quantity of longer-lived DCs in the draining lymph nodes ( Figure 5) . Thus, our data indicate that IL-6 linked with E7 works via two different mechanisms to enhance DNA vaccine potency. IL-6 could enhance E7-specific CD8 + T-cell immunity and anti-tumor effects through enhancing antigen processing and presentation. IL-6 is a secreting cytokine that, when linked to E7, could enhance the antigen processing and presentation of E7 in our murine model (Figure 2) . We also observed that the specific lyses of CTL assays in human peripheral mononuclear cells pulsed with the IL-6/E7 recombinant protein were higher than those after pulsing with wild-type E7 protein on natural human tumor cells (CaSki cells) (Figure 7) . Other studies have demonstrated the advantages of linking IL-6 to E7 in terms of enhancing antigen processing and presentation. This linking has been done with other molecules, including HSP70, domains of exotoxin in Pseudomonas aeruginosa, 18 VP22 of herpes simplex, 19 calreticulin, 3 and vasostatin. 17 IL-6 could enhance E7-specific CD4 + T-cell immunity and anti-E7 antibody responses. IL-6 confers supportive but significant effects on type-1 helper T-cell (Th1)/Th2 responses in T cells. When T cells are stimulated with anti-CD3 and IL-6, their proliferation is significantly enhanced compared with anti-CD3 stimulation alone. IL-6 also affects the Th1/Th2 balance. Rincon et al. showed that IL-6 could induce more Th2 cytokine (such as IL-4) when it is added to a culture of inducing Th differentiation. 20 Thus, IL-6, probably produced by antigen-presenting cells, is a key modulator of Th1/Th2 differentiation. The anti-apoptotic strategy could enhance the potency of antigen-specific DNA vaccines. Other researches have demonstrated that utilizing inhibitors of apoptosis such as Bcl-xL, Bcl-2, XIAP, dominant negative caspase-9, or dominant negative caspase-8 with tumor antigens enhances the antigen-specific immunities and anti-tumor effects. 12, 21, 22 The Bcl-2 protein family comprises key regulators of cell survival that can suppress (e.g., Bcl-2, Bcl-xL, Mcl-1 23 ) or promote (e.g., Bad, Bax) apoptosis. 24 IL-6 has been shown to prolong cell survival via the Mcl-1 pathway. 25 Thus, DC-based vaccination could be enhanced by an approach that inhibits apoptosis and prolongs the survival of antigen-expressing DCs in vivo. 12 Proteins of the Bcl-2 family are known to be over-expressed in some cancers and therefore have been implicated as contributors to cellular immortalization. 26 In an effort to resolve these safety issues, we investigated the capacity of IL-6 to prevent CTL-induced DC death. Because IL-6 is naturally expressed in normal cells, it potentially represents a safe and effective method for enhancing DNA vaccine potency by offering a means of prolonging DC life without risking DC immortalization. 27 Combined strategies of cancer immunotherapy may generate better therapeutic effects than individual strategies. A DNA vaccine with IL-6 encoded with tumor antigens provides combinational strategies of antigen processing and presentation and anti-apoptotic mechanisms. Our results show that both IL-6/E7 and Mcl-1/E7 could provide anti-apoptotic functions for antigen-presenting cells (Figure 5) . However, IL-6/E7 generates higher numbers of E7-specific CD8 + T-cell precursors and therefore may provide better tumor protection and therapeutic effects (Figures 1, 2, and 4) . Our explanation is that IL-6/E7 may work through different strategies such as antigen processing and presentation and anti-apoptosis to generate better immunologic responses and anti-tumor effects than Mcl-1/E7, which is only anti-apoptotic. In addition, our results reveal that the chimeric DNA vaccines IL-6/E7 and ETA(dII)/E7, when mixed together, could generate more potent therapeutic effects than each on its own (Figure 7) .
The IL-6/E7 DNA vaccine, generating humoral and cellmediated immunities, aids both cancer prevention and treatment. Virus-like particles that generate anti-L1 Abs for the prevention of cervical cancer have been developed. The viruslike particles vaccine has been shown to prevent the HPV-16 infection and HPV-16-related cervical intraepithelial neoplasia. 28, 29 However, the virus-like particles vaccine does not provide therapeutic effects against HPV infection or HPV-related lesions. Our IL-6/E7 chimeric DNA vaccine could be utilized for both the prevention of HPV infection and the treatment of HPV-related lesions.
Although the vaccine may hold promise for cancer immunotherapy, some safety issues need to be resolved. DNA may integrate into the host genome, although it is estimated that the frequency of such integration is much lower than the frequency of spontaneous mutation and should not pose a significant risk. 30 Another issue is DNA vaccine-induced autoimmunity. Our results revealed that the titers of anti-IL-6 antibody by IL-6 DNA only (2.236 ± 0.27) were higher than those by wild-type E7 DNA (0.513 ± 0.031) and IL-6/E7 DNA (1.008 ± 0.041) (P < 0.01 one-way ANOVA), so we performed a pathological examination of the vital organs in vaccinated mice. We did not observe abnormal inflammation or pathology (data not shown), indicating that IL-6/E7 is a potent vaccine with minimal side effects.
MATERIALS AND METHODS
Plasmid DNA constructs and preparation. IL-6 was amplified by polymerase chain reaction using human placenta complementary DNA as the template and a set of primers, namely, 5′-CCGCTCGAGAGGAGCCCAG CTATGAACTC-3′ and 5′-CCGGAATTCGACCAGAAGAAGGAATGC CC-3′. The amplified product was then cloned into the XhoI/EcoRI sites of pcDNA3 vector (Invitrogen, Carlsbad, CA). E7 was amplified by polymerase chain reaction using the DNA of the CaSki cell line as the template and with a set of primers, 5′-CCGGAAGCTTATGCATGGAGATACACC TAC-3′ and 5′-CCCAAGCTTTTGAGAACAGATGG-3′. The product was cloned into the HindIII sites of pcDNA3-IL-6 to generate pcDNA3-IL-6/ E7. To generate pcDNA3-Mcl-1/E7, an E7 DNA fragment was also cloned into the HindIII sites of pcDNA3-Mcl-1. To generate pcDNA3-IL-6/E7/ GFP and pcDNA3-Mcl-1/E7/GFP, pcDNA3-IL-6/E7 or pcDNA3-Mcl-1/ E7 was first digested by HindIII. The GFP fragment was obtained from plasmid pcDNA3-E7/GFP by EcoRI/NotI digestion. The DNA fragment was then filled in and ligated into IL-6/E7 or Mcl-1/E7 to generate the desired plasmids. Plasmid constructs were confirmed by sequencing.
Immunoblotting. 293 D b K b cells transfected with various DNA constructs were lysed, 31 resolved on a sodium dodecyl sulfate-containing 12% polyacrylamide gel, and transferred to polyvinylidene difluoride nylon membranes (Millipore, Bedford, MA). They were probed with an antibody specific to E7 (Zymed, San Francisco, CA) or β-actin (Chemicon International, Temecula, CA), and then probed once more with either horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit antibody. The specific bands were visualized using an enhanced chemiluminescence western blot system (Amersham, Buckinghamshire, UK). Our data revealed that the E7 and IL-6/E7 chimeric protein expression levels did not show significant alteration (Figure 8) . Mice. Six-to eight-week-old female C57BL/6J mice were purchased and kept in the animal facility of the College of Medicine, National Taiwan University. There were five mice per group in every experiment. All of the animal procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals.
DNA vaccination. Preparation of DNA-coated gold particles and particlemediated DNA vaccination using a helium-driven gene gun were performed as described previously.
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Intracellular cytokine staining and flow cytometry analysis. Each group of mice was immunized with 2 µg of various DNA vaccines and received a booster 1 week later. Splenocytes were harvested 1 week later and incubated with either 1 µg/ml of E7 peptide (aa 49-57) 33 or 10 µg/ml of E7 peptide (aa 30-67). Cell surface marker staining for CD8 or CD4 and intracellular cytokine staining for IFN-γ or IL-4, as well as flow cytometry analysis, were performed under conditions described earlier. 17, 18 Enzyme-linked immunosorbent assay for anti-E7 antibody. The sera of the mice vaccinated with different DNAs were extracted 14 days after the last immunization. These were used to detect HPV-16 E7-specific Abs by a direct enzyme-linked immunosorbent assay as described by Cheng et al.
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In vivo tumor protection experiments. Each group of mice was immunized with 2 µg of various DNA vaccines and boosted 1 week later. Mice were challenged with 5 × 10 4 cells/mouse TC-1 cells subcutaneously 1 week after their last vaccination. 36 They were then monitored until 60 days after TC-1 tumor challenge.
In vivo antibody depletion experiments. In vivo Ab depletions were performed as described in our previous study. 37 The mice were vaccinated with IL-6/E7 DNA using a gene gun, boosted 1 week later, and challenged with 5 × 10 4 cells/mouse TC-1 tumor cells. Depletion was started 1 week before tumor challenge. Following examples from prior research, we used monoclonal Ab GK1.5 for CD4 depletion, 38 monoclonal Ab 2.43 for CD8 depletion, 39 and monoclonal Ab PK136 for natural killer 1.1 depletion.
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In vivo tumor treatment experiments. Mice were injected with 5 × 10 4 TC-1 cells via their tail veins. Two days later, they received various DNA vaccines (16 µg/mouse). This was followed by a booster every 7 days. The mice were killed and their lungs were removed 28 days after TC-1 cells were injected. The pulmonary tumor nodules in each mouse were evaluated and counted by experimenters who were blind to their sample identity. For a head-to-head comparison of chimeric DNA vaccines, the different vaccines we used were IL-6/E7 DNA only, ETA(dII)/E7 DNA only, 32 IL-6/E7 mixed with ETA(dII)/E7 DNA, followed by a DNA vaccine booster every 7 days. Mice were killed 28 days after TC-1 cell injection to evaluate pulmonary tumor nodules as described above.
